Tashkin, DP; Bateman, ED; Jones, P; Zubek, VB; Metzdorf, N; Liu, D; Leonard, T; Clerisme-Beaty, E; Wise, RA
(2016)
Consistent improvement in health-related quality of life with tiotropium in patients with chronic obstructive pulmonary disease: Novel and conventional responder analyses.
Respiratory Medicine, 120.
pp. 91-100.
ISSN 1532-3064
https://doi.org/10.1016/j.rmed.2016.10.002
SGUL Authors: Jones, Paul Wyatt
Abstract
INTRODUCTION: Improving health-related quality of life (HRQoL) in COPD patients is an important pharmacotherapeutic objective. This study investigated the extent, consistency, and durability of tiotropium maintenance therapy impact on HRQoL in moderate-to-very severe COPD. METHODS: Patients received once-daily tiotropium 18 μg (n = 5244) or placebo (n = 4799) via HandiHaler(®) (10 trials), or once-daily tiotropium 5 μg (n = 2622) or placebo (n = 2618) via Respimat(®) inhaler (3 trials). St George's Respiratory Questionnaire (SGRQ) total scores were measured at baseline, and 6 months (13 trials) and 1 year (9 trials) from treatment start. Adjusted mean differences between treatments for change from baseline in total scores were calculated at each time-point for each trial. Responder and deteriorator rates (decrease or increase in score ≥4 units from baseline, respectively), net benefit (responder rate increase plus deteriorator rate decrease), and cumulative improvement and deterioration were determined. RESULTS: Adjusted mean total score differences between treatments for change from baseline were significant (p < 0.05) in favor of tiotropium in 10/13 trials at 6 months and in 8/9 trials at 1 year. In all trials, estimated differences in responder rates between treatments favored tiotropium (significant [p < 0.05]: 5/13 trials at 6 months; 8/9 trials at 1 year). Net benefit favored tiotropium and cumulative improvement rates were consistently greater and deterioration rates consistently lower for tiotropium versus placebo. CONCLUSIONS: Tiotropium maintenance therapy significantly and consistently improved HRQoL in moderate-to-very severe COPD patients in a durable manner. These results may provide a benchmark for assessing benefits on HRQoL of other COPD treatments.
Item Type: |
Article
|
Additional Information: |
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
Keywords: |
Chronic obstructive pulmonary disease (COPD), Clinical trials, Health-related quality of life, Responder and deteriorator rates, St George's Respiratory Questionnaire (SGRQ), Tiotropium, Chronic obstructive pulmonary disease (COPD), Clinical trials, Health-related quality of life, Responder and deteriorator rates, St George's Respiratory Questionnaire (SGRQ), Tiotropium, Respiratory System, 1102 Cardiovascular Medicine And Haematology, 1103 Clinical Sciences |
SGUL Research Institute / Research Centre: |
Academic Structure > Infection and Immunity Research Institute (INII) |
Journal or Publication Title: |
Respiratory Medicine |
ISSN: |
1532-3064 |
Language: |
ENG |
Dates: |
Date | Event |
---|
1 November 2016 | Published | 11 October 2016 | Published Online | 9 October 2016 | Accepted |
|
Publisher License: |
Creative Commons: Attribution-Noncommercial-No Derivative Works 4.0 |
Projects: |
|
PubMed ID: |
27817821 |
![](http://static.pubmed.gov/portal/portal3rc.fcgi/2745237/img/27842) |
Go to PubMed abstract |
URI: |
https://openaccess.sgul.ac.uk/id/eprint/108442 |
Publisher's version: |
https://doi.org/10.1016/j.rmed.2016.10.002 |
Statistics
Item downloaded times since 12 Dec 2016.
Actions (login required)
![Edit Item](/style/images/action_view.png) |
Edit Item |